Therapeutic targets of kras in colorectal cancer

Shafia Rahman, Shimon Garrel, Michael Gerber, Radhashree Maitra, Sanjay Goel

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations


Patients with metastatic colorectal cancer have a 5-year overall survival of less than 10%. Approximately 45% of patients with metastatic colorectal cancer harbor KRAS mutations. These mutations not only carry a predictive role for the absence of response to anti-EGFR therapy, but also have a negative prognostic impact on the overall survival. There is a growing unmet need for a personalized therapy approach for patients with KRAS-mutant colorectal cancer. In this article, we focus on the therapeutic strategies targeting KRAS-mutant CRC, while reviewing and elaborating on the discovery and physiology of KRAS.

Original languageEnglish (US)
Article number6233
Issue number24
StatePublished - Dec 1 2021


  • Colorectal cancer
  • KRAS mutation
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Therapeutic targets of kras in colorectal cancer'. Together they form a unique fingerprint.

Cite this